Based on cash, and cash equivalents as of September 30, 2025, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into 2029.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- IMRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- 3 Best Stocks to Buy Now, 11/3/2025, According to Top Analysts
- Apple upgraded, Comcast downgraded: Wall Street’s top analyst calls
- Immuneering initiated with an Outperform at Leerink
- Immuneering price target raised to $12 from $10 at Mizuho